{"prompt": "['Study Number: GSP 301-305', 'Version 3.0', 'Date 18-Jul-2018', '8.2.', 'Prior and Concomitant Medications', 'Exclusion of medication prior to the Screening Visit (Visit 1) are summarized in Table 4.', 'Table 4:', 'Summary of Exclusion of Medication Prior to Screening', 'Medication', 'To be Stopped', 'prior Visit 1', '(Days)', 'Vasoconstrictors (eg, epinephrine, sumatriptan).', '3', 'Major tranquilizers (eg, antipsychotics such as chlorpromazine, haloperidol, risperidol,', '3', 'clonazepam).', 'Short-acting antihistamines (oral, ocular, or intranasal antihistaminic - eg, azelastine).', '5', 'OTC cough and cold preparations or sleep aids containing antihistamines.', '7', 'Topical/oral/intanasal decongestants (eg, oxymetazoline, pseudoephedrine, tetrahydrozoline).', '7', 'OTC food supplement/diet to reduce leukotrienes (AIROZIN).', '7', 'Leukotriene antagonists or arachidonate 5-lipoxygenase inhibitors.', '7', 'Inhaled/oral/intranasal anticholinergics.', '7', 'Long-acting antihistamines (eg, cetirizine, fexofenadine).', '10', 'Cromolyn (all forms), nedocromil or lodoxamide (intranasal, ocular, or oral).', '14', 'Systemic antibiotic (see exclusion criterion 17, [Section 7.2]).', '14', 'Ocular mast cell stabilizers.', '14', 'Monoamine oxidase inhibitors.', '14', 'Tricyclic antidepressants.', '14', 'All intranasal/topical/ocular corticosteroids (except study medication - see exclusion criterion', '30', '23 [Section 7.2], and for the treatment of small, localized lesions).', 'Inhaled corticosteroids.', '30', 'Any other investigational non-biological drug.', '30', 'Treatment with any known strong CYP3A4 inducers (eg, carbamazepine, dexamethasone,', '30', 'phenytoin, rifabutin, rifampin, pioglitazone).', 'Treatment with any known strong CYP3A4 inhibitors (eg, azole antifungals, macrolide', '30', 'antibiotics).', 'Systemic corticosteroids (intermittent or chronic, including intra-articular).', '60', 'Immunotherapy injections and immunosuppressive/immune-modulator medications (except', '60', 'topical pimecrolimus cream or tacrolimus ointment if initiated at least 30 days prior to', 'screening and maintained on stable dose, see exclusion criterion 22 [Section 7.2]).', 'IgE antagonist or any other anti-IgE therapy.', '120', 'Any other investigational biological drug', '120', 'Anti-interleukin-5 therapy (eg, reslizumab, mepolizumab)', '120', 'Sublingual immunotherapy (investigational or other).', '180', 'CYP3A4 = Cytochrome P450 system enzyme 3A4; IgE = immunoglobulin E; OTC = over the counter', 'Glenmark', 'CONFIDENTIAL', 'Page 38 of 90']['Study Number: GSP 301-305', 'Version 3.0', 'Date 18-Jul-2018', 'These above medications are also prohibited throughout the entire study (from Screening Visit to', 'Final Visit).', 'In addition to the above medications, concomitant treatment with any of the following', 'medications is prohibited throughout the study (from Screening Visit to Final Visit):', '1. All intranasal therapies (including saline).', '2.', 'Topical corticosteroids (except for the treatment of small, localized lesions).', '3. All ophthalmic drops (prescription and OTC except lens moisturizing drops).', '4. Radiation therapy.', '5. Initiation of immunotherapy.', '6. Any investigational drug being used in another clinical study.', '7.', 'Herbal medication/supplements to treat AR, or any other alternative therapies for AR.', \"8. St John's Wort (Hypericum perforatum).\", '9. Guaifenesin containing products (eg, MUCINEX)', '8.2.1.', 'Exclusion of Concomitant Medications', '1. All above medications (Table 4) are prohibited during the study.', '2. No AR or asthma preventive medication will be permitted during the study except for', 'inhaled short acting beta-agonists for mild asthma (up to 8 puffs per day).', '3.', 'Radiation therapy, the initiation of immunotherapy, and any drug (investigational or', 'marketed) being used in a clinical study are prohibited during the study.', '4. Subjects can receive topical immunotherapy (eg, pimecrolimus cream or tacrolimus', 'ointment), provided initiation of topical immunotherapy was at least 30 days prior to the', 'Screening Visit (Visit 1) and the subject uses a stable maintenance dose (30 days or', 'more) prior to the Screening Visit (Visit 1) as well as during the study.', '5. Strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, and erythromycin) and strong', 'CYP3A4 inducers (eg, carbamazepine, dexamethasone, phenytoin, rifabutin, rifampin,', 'and pioglitazone) are prohibited 30 days prior to the Screening Visit (Visit 1) as well as', 'during the study.', '8.2.2.', 'Permitted Concomitant Medications', 'With the exception of medications listed on the exclusion list, subjects will be allowed to use', 'other chronic medications in stable doses and other medications at the discretion of the', 'Investigator (in consultation with the Sponsor), which do not interfere in the safety and efficacy', 'variables of the study.', '8.2.3.', 'Rescue Medication', 'Rescue medications will not be provided and should not be used throughout the duration of the', 'study, including the placebo run-in period.', 'Glenmark', 'CONFIDENTIAL', 'Page 39 of 90']\n\n###\n\n", "completion": "END"}